Mycophenolate versus Methotrexate in Non-infectious Ocular Inflammatory Disease: A Systematic Review and Meta-Analysis

References

• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513. doi:10.1016/S0002-9394(00)00659-0.
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Moorthy MS, ET C Jr. Drug-induced uveitis. Curr Opin Ophthalmol. 2018;29(6):588–603. doi:10.1097/ICU.0000000000000530.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tundia N, Sorg R, et al. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2016;123(3):655–662. doi:10.1016/j.ophtha.2015.10.028.
   PubMed Web of Science ®Google Scholar
• Wong VG. Methotrexate treatment of uveal disease. Am J Med Sci. 1966;251:239–241.
   PubMed Web of Science ®Google Scholar
• Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm. 2005;13(5):335–351. doi:10.1080/09273940590951034.
   PubMed Web of Science ®Google Scholar
• Shah SS, Lowder CY, Schmitt MA, Wilke WS, Kosmorsky GS, Meisler DM. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992;99(9):1419–1423. doi:10.1016/S0161-6420(92)31790-7.
   PubMed Web of Science ®Google Scholar
• Díaz-Llopis M, Gallego-Pinazo R, García-Delpech S, Salom-Alonso D. General principles for the treatment of non-infectious uveitis. Inflamm Allergy Drug Targets. 2009;8(4):260–265. doi:10.2174/187152809789352203.
   PubMedGoogle Scholar
• Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108(6):1134–1139. doi:10.1016/S0161-6420(01)00576-0.
   PubMed Web of Science ®Google Scholar
• Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs. 2011;16(2):309–322. doi:10.1517/14728214.2011.537824.
   PubMed Web of Science ®Google Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet. 1998;352(9121):35–36. doi:10.1016/S0140-6736(05)79515-5.
   PubMed Web of Science ®Google Scholar
• Rodriguez EE, Sakata VM, Cavalcanti DC, et al. Mycophenolate mofetil as an immunomodulator in refractory noninfectious uveitis. Arq Bras Oftalmol. 2016;79(6):369–372. doi:10.5935/0004-2749.20160105.
   PubMed Web of Science ®Google Scholar
• Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008 Oct 1;115(10):1826–1832. doi:10.1016/j.ophtha.2008.04.026.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014 Oct 1;121(10):1863–1870. doi:10.1016/j.ophtha.2014.04.023.
   PubMed Web of Science ®Google Scholar
• Gangaputra SS, Newcomb CW, Joffe MM, et al. Comparison between methotrexate and mycophenolate mofetil monotherapy for the control of noninfectious ocular inflammatory diseases. Am J Ophthalmol. 2019 Dec 1;208:68–75. doi:10.1016/j.ajo.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. Jama. 2019 Sep 10;322(10):936–945. doi:10.1001/jama.2019.12618.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009 Aug 18;151(4):264–269. doi:10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, D O, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. www.ohri.ca/programs/clinical_epidemiology/oxford.htm
   Google Scholar
• Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010 Mar 1;149(3):423–432. doi:10.1016/j.ajo.2009.09.026.
   PubMed Web of Science ®Google Scholar
• Chang PY, Giuliari GP, Shaikh M, Thakuria P, Makhoul D, Foster CS. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye. 2011 Apr;25(4):427–435. doi:10.1038/eye.2011.23.
   PubMed Web of Science ®Google Scholar
• Lowder CY, Khan M, Hajj-Ali R. Retrospective case series of single center experience of methotrexate and mycophenolate mofetil monotherapy for patients with non infectious posterior, intermediate and panuveitis. Invest Ophthalmol Vis Sci. 2011 Apr 22;52(14):4262.
   Google Scholar
• Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008 Aug 1;115(8):1416–1421. doi:10.1016/j.ophtha.2007.12.011.
   PubMed Web of Science ®Google Scholar
• Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm. 2001 Jan 1;9(1):35–40. doi:10.1076/ocii.9.1.35.3983.
   PubMed Web of Science ®Google Scholar
• Truong T, Kresch Z, Kedhar S, Diaz V, Mauro J, Samson CM. Comparison of methotrexate and mycophenolate in the treatment of chronic uveitis. Invest Ophthalmol Vis Sci. 2013 Jun 16;54(15):124.
   Web of Science ®Google Scholar
• Niemeyer KM, Gonzales JA, Rathinam SR, et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. Am J Ophthalmol. 2017 Jul 1;179:10–17. doi:10.1016/j.ajo.2017.04.003.
   PubMed Web of Science ®Google Scholar